COVID-19 Supplement Approvals Jump, Some On-Time Decision Rates Slip For US FDA
Executive Summary
In FY '21 third quarter, on-time decision rate improved for generics and biosimilars, but dropped again for new drug applications.
You may also be interested in...
Many US COVID-19 Guidances Set To Sunset With Emergency Declaration
But some, including some related to inspections and master protocols, will remain in effect to allow for revisions or a transition out of the pandemic posture.
GDUFA III Talks Completed
Post-warning letter meetings for manufacturing issues and updates to the complex product meeting process are included in the user fee extension agreement.
GDUFA III Talks Completed; Fees will Fund Inspection, Complex Generic Improvements
Post-warning letter meetings for manufacturing issues and updates to the complex product meeting process are included in the user fee extension agreement.